NMN/NR (Nicotinamide Mononucleotide/Riboside) Cost in New Hampshire 2026

What Is NMN/NR and Why Does the Price Vary So Much?

Nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) are NAD+ precursors. Your body converts both molecules into nicotinamide adenine dinucleotide (NAD+), a coenzyme required for mitochondrial energy metabolism, DNA repair via PARP enzymes, and sirtuin-mediated gene regulation. NAD+ tissue concentrations fall roughly 50% between age 40 and age 60 in humans, a finding from Yoshino et al. published in Science in 2021 that helped drive commercial demand for oral precursors.

Price variation comes from three structural factors: raw-material sourcing, whether the product is a branded supplement or a compounded preparation, and the margin stack of the distribution channel. A 500 mg daily NMN capsule from a direct-to-consumer supplement brand retails for anywhere from $60 to $120 per month before shipping. The same molecule dispensed by a 503A compounding pharmacy on a provider's prescription may cost significantly less, depending on the pharmacy's ingredient cost and professional fee. Neither NMN nor NR is reimbursed by any insurer in New Hampshire in 2026, so the full cost lands on the patient regardless of channel.

The NAD+ biology underlying these products is genuinely active research territory. A randomized, placebo-controlled trial in postmenopausal women with prediabetes (N=25) showed that oral NMN at 250 mg/day for 10 weeks improved skeletal-muscle insulin sensitivity and increased expression of genes involved in muscle remodeling, compared with placebo (Yoshino et al., Science 2021). Separate work published in Nature Aging demonstrated that oral NR supplementation raised whole-blood NAD+ metabolite concentrations in healthy older adults (Elhassan et al., Nature Aging 2019 precursor data via PubMed). These trials are small. They do not yet support broad clinical guidelines from bodies such as the Endocrine Society recommending routine prescribing, but they are informing prescriber decisions on telehealth platforms right now.

Average NMN/NR Retail Price in New Hampshire in 2026

The average cash-pay price across New Hampshire retail locations is approximately $80 per month for a standard 300-to-500 mg daily dose of NMN or NR. That figure covers branded supplement bottles sold at natural-foods stores, national supplement chains, and online retailers shipping to NH addresses.

Several pricing tiers exist in practice:

Budget-tier retail (unbranded or store-brand NMN): $40 to $60 per month for 300 mg capsules. Third-party certificate-of-analysis (COA) testing quality is inconsistent at this tier. A 2022 independent analysis of 22 commercially sold NMN supplements found that 9 of 22 products contained less than 80% of the labeled NMN quantity, and 3 contained no detectable NMN at all. Always request a COA when buying at this price point.

Mid-tier branded NMN or NR (e.g., Tru Niagen NR, Elysium Basis): $60 to $90 per month for doses of 250 to 500 mg. These brands publish third-party COAs and, in the case of Tru Niagen, have conducted their own human pharmacokinetic studies demonstrating increased circulating NAD+ metabolites (Trammell et al., Nature Communications 2016).

Premium-tier NMN (stabilized or liposomal formulations): $90 to $150 per month. The clinical evidence that these formulation changes meaningfully increase bioavailability compared with standard oral capsules in humans is limited. One pharmacokinetic study in healthy adults (N=10) showed that a single 250 mg oral NMN dose raised plasma NMN within 2-3 minutes of ingestion (Irie et al., npj Aging 2020), suggesting standard capsule absorption is faster than previously believed. Liposomal claims may be marketing rather than pharmacology.

Compounded NMN via 503A pharmacy: Covered separately below. Pricing ranges from $50 to $90 per month depending on the pharmacy.

New Hampshire Medicaid Coverage for NMN/NR

New Hampshire Medicaid does not cover NMN or NR. Coverage is not available. This applies to the state's fee-for-service Medicaid program and to the managed-care organizations operating under New Hampshire's Medicaid program as of 2026. The reason is straightforward: neither NMN nor NR holds FDA approval as a prescription drug for any indication. Without an approved indication, there is no National Drug Code (NDC) on which a Medicaid claim can be submitted.

The FDA's position on NMN placed NMN on its dietary-supplement ingredient advisory list in 2022, noting that NMN was under investigation as a new drug (IND) at the time. That review remains ongoing. Until the FDA resolves the classification question, compounding pharmacies and telehealth providers operate in a regulatory grey zone that requires a prescription from a licensed provider in New Hampshire to dispense the compound.

No New Hampshire commercial insurer, including Anthem BCBS NH, Harvard Pilgrim, and Ambetter NH, covers NMN or NR. These products are excluded under standard prescription-drug formulary rules because they are not FDA-approved drugs. No prior-authorization pathway exists. The same applies to Medicare Part D plans operating in New Hampshire. Patients should not expect reimbursement from any payer through at least mid-2026.

Compounded Nicotinamide Mononucleotide in New Hampshire: Legality and Access

Compounded NMN is legal in New Hampshire when dispensed by a 503A pharmacy operating under a valid patient-specific prescription. This is a specific legal status. Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed pharmacies to compound drugs for individual patients based on prescriptions from licensed practitioners. New Hampshire follows federal 503A rules without additional state-level restrictions that would block NMN compounding as of 2026.

What does that mean in practice? A New Hampshire-licensed prescriber (MD, DO, NP, or PA with prescribing authority) writes a prescription for compounded NMN at a specified dose and formulation. A 503A pharmacy licensed in New Hampshire or licensed in another state but authorized to ship to NH patients dispenses the compound. The pharmacy must follow USP Chapter 795 standards for non-sterile compounding and must use pharmaceutical-grade NMN as a starting material. This is a meaningfully different quality standard from what applies to supplement manufacturers.

The compounded route does not guarantee lower cost. Pricing depends heavily on which pharmacy fills the prescription, the dose prescribed, and whether the telehealth platform has a preferred-pharmacy relationship that reduces the professional fee. Observed compounded NMN pricing in 2025 to 2026 ranged from $50 to $90 per month for 500 mg daily in oral capsule form.

The HealthRX clinical team uses the following prescribing framework to help patients decide between retail supplement NMN/NR and compounded NMN:

1. Patient wants third-party tested NMN at the lowest cost, no prescription required: Recommend a mid-tier branded supplement (e.g., Tru Niagen NR 300 mg or equivalent NMN brand with published COA). Estimated NH cost: $60 to $80/month.
2. Patient wants pharmaceutical-grade material and provider oversight: Route through telehealth prescription to a 503A pharmacy. Estimated NH cost: $50 to $90/month plus telehealth visit fee.
3. Patient is on a protocol that also includes other longevity or metabolic compounds (e.g., metformin, semaglutide): Compounded route preferred because the provider is already monitoring labs, and pharmaceutical-grade sourcing reduces variability in a multi-compound protocol.
4. Patient has prediabetes or insulin resistance and is asking about NMN specifically: Reference the Yoshino et al. 2021 Science trial, discuss realistic expectations (skeletal-muscle insulin sensitivity signal at 250 mg/day over 10 weeks in postmenopausal women with prediabetes), order fasting insulin and HbA1c at baseline, and set a 90-day reassessment point.

Telehealth Access to NMN/NR in New Hampshire

Telehealth prescribing of NMN is legal in New Hampshire. A provider licensed in New Hampshire may conduct a synchronous or asynchronous telehealth visit and, if clinically appropriate, issue a prescription for compounded NMN to a 503A pharmacy. New Hampshire follows the interstate telehealth prescribing rules established under the Ryan Haight Online Pharmacy Consumer Protection Act for controlled substances. NMN is not a controlled substance, so the prescribing rules are less restrictive. A valid prescriber-patient relationship, established via telehealth, is sufficient.

New Hampshire participates in the Interstate Medical Licensure Compact (IMLC), which means out-of-state providers credentialed through the compact can legally treat NH patients via telehealth. Many longevity-focused telehealth platforms use this compact to serve patients in multiple states from a single provider team. The practical implication is that NH patients have access to a broad pool of telehealth providers who can evaluate NAD+ precursor therapy and write a compounded NMN prescription.

The American Telemedicine Association has published standards for telehealth prescribing that emphasize documentation of clinical rationale, informed consent, and follow-up planning. Responsible prescribers in this space will typically review baseline labs (fasting glucose, HbA1c, comprehensive metabolic panel) before starting NMN on a patient, particularly given that the human trial evidence is still emerging. The most-cited mechanistic paper supporting NMN's effect on human metabolism, Yoshino et al. 2021 in Science, enrolled only 25 women (PubMed). Prescribers should communicate that limitation clearly.

Additional relevant pharmacology: a separate 2020 study by Irie et al. demonstrated that a single oral NMN dose raised plasma NMN levels in humans within minutes, with peak blood NMN at approximately 2.5 hours post-dose in a cohort of healthy men (PubMed). That kinetic profile supports once-daily morning dosing, which is the standard frequency used in most NH telehealth protocols.

How NAD+ Precursor Biology Supports the Clinical Rationale

Understanding why providers prescribe NMN or NR requires a brief look at the biology. NAD+ is required for the activity of sirtuins (SIRT1-7), which regulate mitochondrial biogenesis, inflammation, and DNA repair. It is also a required substrate for PARPs (poly-ADP-ribose polymerases), which repair single-strand DNA breaks. Age-related NAD+ decline may therefore contribute to accumulating DNA damage and declining mitochondrial function.

A landmark 2013 paper by Gomes et al. in Cell showed that declining SIRT1 activity in aged muscle caused pseudohypoxia and mitochondrial dysfunction, and that NMN supplementation for one week restored mitochondrial function in aged mice (PubMed). Mouse data does not translate directly to human clinical outcomes, but it established the mechanistic rationale that drove subsequent human trials.

In humans, the most strong evidence so far involves insulin sensitivity and skeletal-muscle gene expression (Yoshino et al. 2021), NAD+ metabolite elevation in blood (multiple NR trials), and one small trial showing NMN improved muscle performance in older adults. A 2021 trial by Huang et al. in GeroScience (N=48) showed that NMN 250 mg/day for 12 weeks significantly improved muscle strength and performance in older adults aged 65 and above versus placebo (PubMed). The trial was small. Replication in larger cohorts is needed before these findings can be considered definitive.

The National Institute on Aging is actively funding NAD+ biology research, acknowledging NAD+ decline as a plausible contributor to aging biology. No NIA guideline currently recommends routine NMN or NR supplementation in clinical practice, though several NIA-funded investigators are running Phase 2 trials as of 2025.

Safety Profile and Drug Interactions Relevant to NH Prescribers

NMN and NR have a favorable short-term safety profile in completed human trials. The most common adverse effects are mild GI symptoms (nausea, loose stools) reported in roughly 5 to 15% of participants at doses of 1 to 000 mg/day or above. At the 250 to 500 mg/day range used in most clinical trials, adverse events were not significantly different from placebo (Trammell et al., Nature Communications 2016).

Clinicians prescribing NMN or NR in New Hampshire should note the following potential interactions:

With PARP inhibitors (olaparib, niraparib, rucaparib): NMN is a NAD+ precursor, and PARP activity depends on NAD+. Theoretically, raising NAD+ levels could reduce the efficacy of PARP inhibitors used in oncology, though no human trial has evaluated this interaction directly. Providers should not prescribe NMN alongside PARP inhibitor therapy without oncology input. The FDA drug interaction guidance does not list NMN as a formal interaction risk, but the pharmacological logic warrants caution.

With resveratrol: Many longevity protocols combine NMN with resveratrol because resveratrol may activate SIRT1 and NMN provides the NAD+ substrate SIRT1 requires. This combination is popular on telehealth platforms. The human evidence for the combination is limited; David Sinclair's lab at Harvard has studied this pairing in mice but no combination RCT in humans has been completed.

With metformin: Metformin inhibits mitochondrial complex I, which affects cellular NAD+/NADH ratios. Some clinicians argue the combination is counterproductive; others prescribe both for patients with prediabetes and insulin resistance. The clinical data does not yet resolve this question. Monitor HbA1c and fasting glucose at 90-day intervals if both are prescribed simultaneously.

Long-term safety data beyond 12 months of continuous use does not exist from controlled trials in humans. Providers should discuss this gap with patients during informed consent.

Ways to Reduce the Cost of NMN/NR in New Hampshire

Insurance does not help here. The cost-reduction strategies that work in NH are:

Buy direct from manufacturer with a subscription: Most NMN/NR supplement brands offer 10 to 20% discounts on auto-ship subscriptions. On an $80/month product, that saves $8 to $16 per month, or $96 to $192 per year.

Use a 503A compounding pharmacy with transparent pricing: Some compounding pharmacies offer lower per-capsule pricing than branded supplements when the order is for a 90-day supply. A 90-day compounded supply at $60/month billed as a single $180 fill is common on telehealth platforms. Compare the per-month cost of compounded vs. retail before choosing a channel.

Ask about telehealth platform bundles: Several longevity telehealth platforms bundle the provider visit fee, lab work, and the prescription compound into a monthly membership fee of $99 to $199. For a patient who would otherwise pay $80 for retail NMN plus $150 for a lab draw plus a provider visit fee, the bundle may be net cheaper.

HSA/FSA eligibility: Prescription NMN dispensed by a 503A pharmacy on a valid prescription may be HSA/FSA eligible, because it is a prescribed compound. Retail supplement NMN is generally not HSA/FSA eligible. Patients with HSA balances should route through the prescription channel to use pre-tax dollars. IRS Publication 502 governs medical expense deductibility and HSA-eligible expenses; confirm eligibility with your HSA plan administrator before assuming coverage.

Generic or bulk-powder NMN: Some suppliers sell bulk NMN powder for self-encapsulation at significantly lower per-gram cost. This approach bypasses any quality assurance and is not recommended by the HealthRX medical team, but it exists in the market and patients may ask about it.

Patient assistance or discount programs: No manufacturer currently operates a patient-assistance program for NMN or NR in the way that pharmaceutical companies operate PAPs for brand-name drugs. GoodRx and RxSaver do not carry NMN pricing because it is not an FDA-approved drug with an NDC. There are no New Hampshire state discount programs for NMN or NR.

What to Expect at a New Hampshire NMN Telehealth Appointment

A first telehealth visit for NMN evaluation in New Hampshire typically runs 20 to 30 minutes. The provider will review your health history, current medications, relevant labs (fasting glucose, HbA1c, lipid panel, CMP), and your goals for NAD+ precursor therapy. They will discuss the current state of the evidence, including the limitation that the largest human NMN trial to date enrolled 48 subjects (Huang et al., GeroScience 2021), and that no long-term safety data beyond 12 months exists.

If the provider determines NMN is appropriate, they will write a prescription for a specific dose (most commonly 250 to 500 mg/day), specify oral capsule or sublingual tablet, and route it to a 503A pharmacy of your choice or a platform-affiliated pharmacy. Lab follow-up is typically scheduled at 90 days to assess any changes in metabolic markers.

The visit fee for a telehealth longevity consultation in New Hampshire ranges from $75 to $200 for the initial visit, with follow-up visits at $50 to $100. Some platforms include follow-up in a monthly membership fee. No commercial insurer in New Hampshire covers the visit for the specific purpose of NMN prescribing in 2026, though some plans may apply the visit to a general preventive-medicine benefit depending on how the provider codes the encounter. Patients should confirm with their insurer before the visit.

As the National Institutes of Health Office of Dietary Supplements notes, NAD+ precursor research is an active area with promising early-phase human data, but current evidence is insufficient to support population-level supplementation recommendations. New Hampshire patients considering NMN therapy should approach the decision with clear goals, realistic expectations, and a provider who will monitor outcomes systematically.

Patients starting NMN for the first time should begin at 250 mg/day with food for at least four weeks before considering dose escalation to 500 mg/day.